Efficacy Assessment of Radiofrequency Ablation as a Palliative Pain Treatment in Patients with Painful Metastatic Spinal Lesions: A Systematic Review

Katharina Rosian, MSc, Katharina Hawlik, MD, and Brigitte Piso, MD

Background: Metastatic spinal lesions are difficult-to-treat entities that are most commonly associated with pain and severely reduced health-related quality of life (HRQoL). Within the last 5 to 10 years, radiofrequency ablation (RFA) has emerged as an option in the palliative treatment of vertebral metastases.

Objectives: Our review aims to evaluate the clinical effectiveness and safety of RFA, mostly in combination with vertebroplasty, in patients with painful vertebral metastases.

Study Design: The design of this study is a systematic review.

Methods: We conducted a systematic literature search and a manual search of 5 databases in December 2016. The review applied a methodological framework based on the HTA Core Model®. Data on each selected outcome category were synthesized according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) scheme. Risk of bias was assessed using the Institute of Health Economics (IHE) Risk of Bias checklist for case series.

Results: We identified 299 citations. After applying the inclusion criteria, a total of 9 studies (4 prospective and 5 retrospective studies) were determined to be eligible. These studies included a total of 583 patients with vertebral metastases who were treated with RFA and, in most cases, received an additional vertebroplasty treatment (n = 437). The studies were categorized as having a moderate to high risk of bias. The strength of evidence was found to be “very low” for safety outcomes and could not be assessed for efficacy outcomes. Current evidence suggests that RFA leads to significant pain reduction. Furthermore, no major complications occurred when using RFA.

Limitations: A major concern is the low number of included patients and heterogeneity of study characteristics in most of the studies. The low number of patients also impeded comparison of the effectiveness of RFA alone to RFA in combination with vertebroplasty.

Conclusion: According to the available evidence, RFA may be safe and effective, especially for patients with painful vertebral metastases who show contraindications or unresponsiveness to conventional therapies (e.g., radiation) or for those who are at risk of tumor progression.

Key words: Radiofrequency ablation, vertebral metastases, metastatic spinal lesions, pain, clinical effectiveness, safety, palliative pain treatment

Pain Physician 2018; 21:E467-E476

Bony metastases are very difficult to treat and often unresponsive to conventional treatments (1). The vertebrae are most frequently affected by metastases, accounting for 40% of all bone metastatic lesions. At the time of death, about 80% of cancer patients are affected by bone metastases, and of those, about 50% are affected by vertebral metastases (2-4).

Over the last 2 decades, there has been substantial progress in the symptomatic treatment of unresect-
able tumors and metastases in the area of the spine. Treatment options include cytoreductive therapies, i.e., radiation, hormonal ablation, and chemotherapy; and treatments that do not directly attack the tumor cells, but inhibit osteoclast activity (4,5). In some patients, however, none of these treatment options provide sufficient symptom control.

In the last 5 to 10 years, radiofrequency ablation (RFA) has emerged as a feasible option in the palliative treatment of vertebral metastases because of short procedure times, its minimal invasiveness, and its capacity to be performed on an ambulatory basis (5,6). RFA was first described in 1992 as an auspicious technique for the treatment of osteoid osteomas by Rosenthal et al (7-9). At present, RFA is used as an image-guided, minimally invasive thermal ablation procedure for solid tumors (10,11). A metastasis adjacent to neurological structures, however, can present a contraindication with RFA due to the risk of neurological injury and secondary fractures of large lesions in the vertebrae (12).

The present systematic review aimed to evaluate the clinical effectiveness and safety of RFA with and without vertebroplasty in comparison to the standard of care (e.g., radiotherapy) for patients with painful vertebral metastases for whom a curative tumor treatment was not indicated or symptomatic improvement did not occur even after reaching a maximal radiation dose; outcomes included pain, functional status, health-related quality of life (HRQoL), and complications.

**Methods**

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (13). The systematic review is based on 4 domains of the HTA (Health Technology Assessment) Core Model® developed within the European Network for Health Technology Assessment (EUnetHTA); these domains include 1) health problem and current use of technology (CUR), 2) description and technical characteristics of technology (TEC), 3) safety (SAF), and 4) clinical effectiveness (EFF) (14).

**Literature Searches**

We performed a systematic literature search in the following databases: Ovid MEDLINE, Embase, the Cochrane Library, CRD (DARE, NHS-EED, HTA), and PubMed (Appendix 1). Our systematic search was not limited to a specific study design or time period (from the earliest records to December 2016). The systematic literature search was completed by a manual search for additional records, using the keywords “radiofrequency,” “ablation,” “spine,” and “metastases.” Abstracts were screened by 2 independent researchers.

**Eligibility Criteria**

Inclusion criteria for relevant studies were as follows: 1) patients with solitary fracture-related vertebral metastases of all entities, for whom a curative tumor treatment (vertebral body extension and stabilization) was not indicated, or for whom symptomatic improvement did not occur given maximal radiation dose or radiation-resistant lesions; 2) RFA with or without vertebroplasty or other add-on therapies (e.g., radiation); 3) randomized controlled trials (RCTs), nonrandomized controlled trials (NRS), prospective and retrospective case series; 4) sample > 30 patients in retrospective studies; 5) published in English or German; 6) sub-analytical results were excluded if already published by the same investigator in a previous article.

**Data Extraction**

Two reviewers independently extracted data from eligible studies for inclusion in predefined tables. The extraction table summarizes the following characteristics: study design, demographic characteristics, intervention, sponsoring, setting, mean duration of intervention, follow-up period, total vertebral treated metastatic bodies/lesions, efficacy outcomes (increased pain, functional status, health-related quality of life (HRQoL), satisfaction with treatment, recurrence of vertebral metastases, mortality), as well as safety outcomes (major complications, procedure-related adverse events, and non-procedure-related adverse events).

**Methodological Quality Assessment**

Data on each selected outcome category were synthesized across studies according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) scheme (15). Each study was rated by two independent researchers. A third researcher was called to resolve differences in case of disagreement. The GRADE scheme uses 4 categories to rank the strength of evidence of included studies (Table 1). A more detailed list of applied criteria can be found in the recommendations of the GRADE Working Group (15).

No further data processing (e.g., indirect comparison) was conducted. The studies were systematically assessed for quality and risk of bias by 2 independent researchers using the Institute of Health Economics.
(IHE) Risk of Bias checklist for case series (16) (Fig. 1). A third researcher was called to resolve differences in case of disagreement. We extended the checklist for an overall rating that measured risk of bias, ranging from low to moderate to high, to enable comparison of the studies with each other (Table 2).

**Results**

**Study Selection**

In total, 299 citations were identified through the systematic search. After abstract screening, 58 full texts were assessed for eligibility. A total of 9 articles, 4 prospective single-arm and 5 retrospective single-arm studies, partly multicenter, were included (4-7, 17-21). Five studies with subgroup analyses (22-26) were additionally included to compare findings and patient characteristics. However, since they presented sub-analyses of results of already included papers (4,5,18,21), we excluded them from the final analyses.

**Study Characteristics**

A total of 604 patients (293 women, 219 men, 92 not specified) were enrolled in the included studies, of which 583 patients had vertebral metastases. These patients suffered from severe pain and were unresponsive to previous treatments (e.g., analgesics, radiation, or chemotherapy). The mean age ranged from 61.0 to 69.6 years across studies. One study did not report baseline characteristics for age and gender (4). The mean follow-up periods differed considerably, with a range of 24–48 hours to 60 months of post-treatment follow-up.

A variety of ablation systems were used in the studies; the most commonly used were the STAR® Tumor Ablation System (DFine Inc., San Jose, CA) and the CAVITY SpineWand® (ArthroCare Corporation, Austin, TX). The majority of patients (437; 72.4%) received additional vertebroplasty treatment following RFA. One study did not report the number of patients who received vertebroplasty, but did report that vertebroplas-

Table 1. **GRADE categories to rank the strength of evidence (15).**

<table>
<thead>
<tr>
<th>Category</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>We are very confident that the true effect lies close to that of the estimate of the effect</td>
</tr>
<tr>
<td>Moderate</td>
<td>We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different</td>
</tr>
<tr>
<td>Low</td>
<td>Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect</td>
</tr>
<tr>
<td>Very Low</td>
<td>Evidence is either unavailable or does not permit a conclusion</td>
</tr>
</tbody>
</table>

![Risk of Bias Checklist](https://example.com/risk_of_bias_checklist.png)

**Fig. 1.** Reporting and risk of bias – study level (case series), (n = 9).
### Table 2. Study characteristics of individual studies included in the analysis, sorted by year.

<table>
<thead>
<tr>
<th>Ref. No.</th>
<th>First Author</th>
<th>Year</th>
<th>Title</th>
<th>Country</th>
<th>Sponsor</th>
<th>Ablation system</th>
<th>Study type</th>
<th>No. of patients</th>
<th>Mean age of patients, years (SD)</th>
<th>Follow-up (months)</th>
<th>Loss to follow-up, n (%)</th>
<th>Overall risk of biasa</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6)</td>
<td>Bagla</td>
<td>2016</td>
<td>Multicenter prospective clinical series evaluating radiofrequency ablation in the treatment of painful spine metastases</td>
<td>USA</td>
<td>DFINE Inc.</td>
<td>STAR Tumor Ablation System (DFine Inc., USA)</td>
<td>Multicentre prospective study</td>
<td>50</td>
<td>61.0, range 23-83 (13)</td>
<td>3</td>
<td>16 (32) at 3 months</td>
<td>Moderate</td>
</tr>
<tr>
<td>(5)</td>
<td>Dabravolski</td>
<td>2015</td>
<td>Tumours and metastases of the spine: Cavity/coblation surgery and vertebroplasty/kyphoplasty</td>
<td>Germany</td>
<td>NR</td>
<td>CAVITY SpineWand (ArthroCare Corporation, USA)</td>
<td>Single-centre retrospective study</td>
<td>250</td>
<td>65.5, range 31-92</td>
<td>60</td>
<td>7 (3.1)</td>
<td>High</td>
</tr>
<tr>
<td>(20)</td>
<td>Wallace</td>
<td>2015</td>
<td>Radiofrequency ablation and vertebral augmentation for palliation of painful spinal metastases</td>
<td>USA</td>
<td>NR</td>
<td>STAR Tumor Ablation System (DFine Inc., USA)</td>
<td>Single-centre retrospective study</td>
<td>72</td>
<td>68.4 (18.8)</td>
<td>1</td>
<td>8 (11.1)</td>
<td>High</td>
</tr>
<tr>
<td>(4)</td>
<td>Anchala</td>
<td>2014</td>
<td>Treatment of metastatic spinal lesions with a navigational bipolar radiofrequency ablation device: A multicenter retrospective study</td>
<td>USA</td>
<td>NR</td>
<td>STAR Tumor Ablation System (DFine Inc., USA)</td>
<td>Multicentre retrospective study</td>
<td>92</td>
<td>NR</td>
<td>6</td>
<td>9 at 1 month (9.8)</td>
<td>High</td>
</tr>
<tr>
<td>(16)</td>
<td>Gazis</td>
<td>2014</td>
<td>Bipolar radiofrequency ablation of spinal tumors: Predictability, safety and outcome</td>
<td>Germany</td>
<td>NR</td>
<td>CelonLab Power and Celon Aquaflow III (Celon AG Medical Instruments, Germany)</td>
<td>Single-centre prospective study</td>
<td>36</td>
<td>67.8, range 40-84</td>
<td>NR</td>
<td>NR</td>
<td>High</td>
</tr>
<tr>
<td>(17)</td>
<td>Georgy</td>
<td>2009</td>
<td>Bone cement deposition patterns with plasmamediated radio-frequency ablation and cement augmentation for advanced metastatic spine lesions</td>
<td>USA</td>
<td>ArthroCare Corporation</td>
<td>CAVITY SpineWand (ArthroCare Corporation, USA)</td>
<td>Single-centre retrospective study</td>
<td>37</td>
<td>69.6, range 34-89</td>
<td>2-4 weeks</td>
<td>9 (24)</td>
<td>Moderate</td>
</tr>
<tr>
<td>(19)</td>
<td>Nakatsuka</td>
<td>2009</td>
<td>Percutaneous radiofrequency ablation of painful spinal tumors adjacent to the spinal cord with real-time monitoring of spinal canal temperature: A prospective study</td>
<td>Japan</td>
<td>NR</td>
<td>Cool-tip RF Ablation System (Valleylab, USA)</td>
<td>Single-centre prospective study</td>
<td>10</td>
<td>61.0, range 52-78 (13)</td>
<td>4.5, range 27.7-1.1 (SD 1.3)</td>
<td>0</td>
<td>High</td>
</tr>
</tbody>
</table>
RFA as Palliative Pain Treatment for Vertebral Metastases

<table>
<thead>
<tr>
<th>Ref. No.</th>
<th>First Author</th>
<th>Year</th>
<th>Title</th>
<th>Country</th>
<th>Sponsor</th>
<th>Ablation system</th>
<th>Study type</th>
<th>No. of patients</th>
<th>Mean age of patients (SD)</th>
<th>Follow-up (months)</th>
<th>Loss to follow-up, n (%)</th>
<th>Overall risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>(7)</td>
<td>Proschek</td>
<td>2009</td>
<td>Prospective pilot-study of combined bipolar radiofrequency ablation and application of bone cement in bone metastases</td>
<td>Germany</td>
<td>NR</td>
<td>Celon Pro Surge &amp; CelonPOWER System (Celon AG Medical Instruments, Germany)</td>
<td>Single-centre prospective pilot-study</td>
<td>16</td>
<td>59.5, range 52-69</td>
<td>20.4, range 8-36</td>
<td>NR</td>
<td>Moderate</td>
</tr>
<tr>
<td>(18)</td>
<td>Gevargez</td>
<td>2008</td>
<td>Image-guided radiofrequency ablation (RFA) of spinal tumors</td>
<td>Germany</td>
<td>NR</td>
<td>Radionics System &amp; RITA Medical System (Radionics Inc., USA &amp; RITA Medical System Inc., USA)</td>
<td>Single-centre retrospective study</td>
<td>41</td>
<td>62.7, range 46-82 (9)</td>
<td>&gt; 6 (278-617 days)</td>
<td>25 (61)</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

Abbreviations: NR not reported, SD standard deviation. *According to the IHE Risk of Bias checklist for case series (16).

Table 2 cont.). Study characteristics of individual studies included in the analysis, sorted by year.

Effectiveness of RFA

No comparative studies assessing the clinical effectiveness and safety outcomes of RFA for metastatic spinal lesions could be identified. Nevertheless, 4 prospective studies of the clinical effectiveness of RFA examined pain reduction outcomes (6,7,17,20). Three of these studies reported significant pain relief after treatment with RFA (6,7,20). The fourth study only stated the proportion of patients (52.8%) who reported post-interventional pain reduction and did not specify the pain measure used (7). In pain at 1 and 3 months, a decrease of 3.3 and 3.8 points, respectively (P < 0.0001). The fourth study also described a decrease in pain at 1 month (P < 0.018) or RFA in combination with vertebroplasty (decrease of 2.4, P < 0.005). Furthermore, they showed that pain levels continued to decline 15-36 months after baseline (decrease of 2.6, P < 0.005). In pain at 1 and 3 months, a decrease of 3.3 and 3.8 points, respectively, P < 0.0001. The fourth study also described a decrease in pain at 1 month (P < 0.018) or RFA in combination with vertebroplasty (decrease of 2.4, P < 0.005). Furthermore, they showed that pain levels continued to decline 15-36 months after baseline (decrease of 2.6, P < 0.005). In pain at 1 and 3 months, a decrease of 3.3 and 3.8 points, respectively (P < 0.0001). Overall, the strength of evidence for clinical effectiveness is low, due mainly to missing data for control groups and overlapping samples of patients in 3 studies (3).

Quality of Evidence

The risk of bias was assessed for the 9 studies according to the IHE checklist (16). The overall risk of bias is presented in Table 2. None of the studies were categorized with a low risk of bias; 4 studies showed a high risk of bias due to unclear reporting of randomization, and 5 studies showed a moderate risk of bias due to unclear reporting of randomization, allocation concealment, and missing data. Overall, the quality of evidence is low, due mainly to missing data for control groups and overlapping samples of patients in 3 studies (3).
Fig. 2. PRISMA flow diagram outlining selection process for included studies.

Outcomes for the progression or recurrence of vertebral metastases were only observed in one prospective study, in which none of the patients had a local relapse after treatment with RFA or RFA in combination with vertebroplasty (7).

HRQoL was assessed by 2 studies using different measures: Bagla et al (6) applied the Functional Assessment of Cancer Therapy-General 7 (FACT-G7) and the Functional Assessment of Cancer Therapy Quality-of-Life Measurement in Patients with Bone Pain (FACT-BP) (6); the other study, Proschek et al (7) used the Oswestry Disability Questionnaire. Bagla et al (6) reported statistically significant improvements throughout 1 month and 3 months of treatment, with a FACT-G7 improvement of 4.8 and 5.2, respectively, and a FACT-BP improvement of 14.7 and 16.3, respectively, compared to baseline. Back-related disability was also assessed, with patients showing statistically significant improvements from baseline (52.9%) to 1 month (40%) to 3 months (37%); these changes represent an improvement in functional status from severe to moderate disability (Modified Oswestry Disability Index) (6). Using the Oswestry Disability Questionnaire, Proschek et al (7) observed significant improvements of 30% after 3-6 months for patients treated with RFA and after 15-36 months for patients treated with RFA and vertebroplasty, compared to
RFA as Palliative Pain Treatment for Vertebral Metastases

Table 3. Evidence profile: Efficacy and safety of radiofrequency ablation for metastatic spinal lesions (GRADE).

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Estimate of Effect</th>
<th>Study Limitations</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Other Modifying Factors</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/112 Prospective single arm studies</td>
<td>20/112 (17.9%); Range: 19.4-40%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>5/471(^d) Retrospective single arm studies</td>
<td>58/471 (12.3%); Range: 4.3-21.9%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>Major complications (procedure-related) *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/112 Prospective single arm studies</td>
<td>0</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>5/471(^d) Retrospective single arm studies</td>
<td>0</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>Adverse events (procedure-related)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/112 Prospective single arm studies</td>
<td>5/112 (4.5%); Range: 10-11.1%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>5/471(^d) Retrospective single arm studies</td>
<td>11/471 (2.3%); Range: 0-9.8%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>Adverse events (not procedure-related)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/112 Prospective single arm studies</td>
<td>15/112 (13.4%); Range: 8.3-30%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
<tr>
<td>5/471(^d) Retrospective single arm studies</td>
<td>74/471 (15.7%); Range: 4.3-73%</td>
<td>Serious limitations (-1)(^a)</td>
<td>0</td>
<td>Direct</td>
<td>Imprecise data (-1)(^b)</td>
<td>Very low</td>
</tr>
</tbody>
</table>

Nomenclature for GRADE table:
- Limitations: 0: no limitations or no serious limitations; -1: serious limitations
- Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency
- Indirectness: 0: direct, no uncertainty; -1: some uncertainty; -2: major uncertainty
- Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), plausible confounding (+1)
* None of the included studies reported any serious adverse events related to the procedure.
\(^a\)Due to the lack of a controlled group, no data on efficacy outcomes can be compared and synthesized.
\(^b\)No control group.
\(^d\)Small numbers of patients in included studies.
\(^2\)2 patients of (21) may already be included in another retrospective study (4).
\(^\)Overlap of patients in 2 studies.

baseline. In summary, these 2 studies suggest that RFA leads to significant pain reduction as well as improvement in HRQoL.

Since the treatment with RFA for vertebral metastases is palliative and does not aim to prolong life, mortality outcomes were reported in only 2 studies, and ranged from 5 to 10 deaths during each study’s follow-up period of 3 and 4.5 months, respectively (6,20).

**Safety of RFA**

In terms of safety, all of the 9 included studies reported complications; however, no major complications
occurred in any of the studies. The overall complication rates were similar across all but 2 studies (18,20). Higher complication rates in these 2 studies might be related to different follow-up periods (2-4 weeks vs. 4.5 months) and the stage of the disease.

Overall, out of the 583 patients with vertebral metastases included across all 9 studies, adverse events (procedure-related or non-procedure-related) occurred in 105 patients (18.0%) who completed follow-up. Occurrence of adverse events related to RFA ranged from 5.6% to 11.1% of the patients in each study. Increased pain and numbness (6/583) (17,19), and post-procedure radicular symptoms and pain (5/583) (18,21) were the most frequently described procedure-related adverse events. Procedure-related adverse events were not reported in 4 of the included studies (4-7).

Rates of adverse events that were not RFA-related (but vertebroplasty-related) ranged from 4.3% to 73.0%. Thereby, cement extravasation after vertebroplasty was the most frequently reported, occurring in 15.3% of patients (67/437) (4,5,18). One study did not report any RFA-unrelated adverse events (21).

**Discussion**

Vertebral metastases are difficult-to-treat entities that most frequently affect patients who are suffering from breast, lung, or prostate cancer. Most commonly, these metastases are associated with progressive pain and severely reduced HRQoL. Furthermore, untreated or progressing spinal metastases can lead to pathological fractures and spinal instability, hypercalcemia, or spinal cord compression (5,6,27).

Individual studies have used differing RFA systems and interventions, warranting a comparison. For instance, the RFA systems applied in the studies included in this review differed with respect to the temperature used for ablation: the STAR® Tumor Ablation System (DFine Inc., San Jose, CA) uses up to 50°C, whereas the CAVITY-SpineWand® (ArthroCare Corporation, Austin, TX) only uses cold energy at 42°C. Studies also differed with respect to ablation method: the STAR® Tumor Ablation System has a bipolar extensible radiofrequency electrode at the top of the articulated distal segment. The segment can be curved up to 90° and is therefore able to access multiple areas of the tumor. This system also comprises a combination of 2 thermocouples, which enable real-time temperature monitoring (2,34). In contrast, the CAVITY-SpineWand® probe creates a cavity in the tumor tissue by plasma generation (cobloration-controlled ablation) at a low temperature on the basis of plasma-mediated high-frequency energy. Coblation (radiofrequency-based plasma ablation) refers to a controlled ablation with a pre-bent plasma probe. The probe can be rotated so that the ablation can take place in several directions. Coblation can be combined with additional procedures, in particular with vertebroplasty (5,22,23). Finally, patients across these studies differed with regard to their histories of treatment with additional therapies, such as radiation therapy or analgesics, before or following RFA.

It is possible that these therapies and the different RFA systems have had a confounding effect on the outcomes of the studies (such as pain and HRQoL). Further, it should be recognized that most of the effectiveness outcomes were patient-reported and hence subject to a high risk of bias.

A major concern of most of the identified prospective studies was the low number of included patients; one study, for instance, only included 10 patients (20). In order to identify rare complications, low patient numbers are insufficient. Furthermore, the inclusion criteria were slightly different among studies, with different entry points. To determine the best time for the initiation of treatment studies, including more patients and having similar entry points would be useful.

Moreover, the follow-up period varied substantially between studies, ranging from 24-48 hours to 60 months post-treatment, including 2 studies that had a very short follow-up period of 2-4 weeks (18,21) and one study that observed its patients only 24-48 hours post-treatment (17). Reliable data on long-term safety and efficacy outcomes are missing. However, long-term follow-up is challenging for patients with metastatic spinal lesions due to high morbidity and mortality rates – making data collection extremely difficult. The question of meaningful long-term follow-up periods for terminal patients is an important consideration.

For 2 of the included retrospective studies, it can be assumed – though it is not clearly stated – that the observed patient populations overlap, since some of the 72 patients included in Wallace et al seem to be included among the 92 patients of Anchala et al (4,21). The outcomes of these studies were reported separately, but data may be imprecise as a result.

RFA for vertebral metastases is associated with low numbers of complications and does not require the interruption of adjuvant therapies (e.g., radiation or chemotherapy) (5,21). Due to the advancing nature of the disease, however, an associated vertebroplasty in addi-
tion to RFA is common. A recently published Guideline on Percutaneous Vertebral Augmentation recommends treatment with vertebroplasty following different tumor treatments (like RFA) in patients with painful vertebrae due to metastases in order to achieve pain relief and the consolidation of vertebra (30). Hence, while additional vertebroplasty may be indicated following RFA (18,28,29), it can limit the ability to adequately assess the efficacy of RFA; vertebroplasty may also be a confounder of the post-interventional pain evaluation. In all of the studies included for this review, vertebroplasty was performed if there was a risk of fracture and instability of the bone structure due to tumor removal. Therefore, an evaluation of the effect of RFA alone in comparison to RFA in combination with vertebroplasty was not feasible due to the low number of cases in the studies. A comparative study design or larger numbers of patients will be required to compare the effect of RFA in combination with vertebroplasty and RFA alone for the treatment of painful vertebral metastases.

The present systematic review indicated that there is presently only limited evidence for the clinical effectiveness and safety of RFA treatment for vertebral metastases. Furthermore, systematic reviews that analyzed RFA for lung tumors, malignant biliary obstruction, or small renal neoplasms have also shown that the level of evidence is low, with no RCTs comparing the use of RFA with other treatment options. Nevertheless, RFA may also be a safe and effective treatment option for lung tumors, malignant biliary obstruction, and small renal neoplasms (31-33).

Despite the heterogeneity of study characteristics, the included case series show that image-guided RFA with or without vertebroplasty might be a feasible and safe technique for patients with painful metastatic spinal lesions – particularly since no serious complications were reported. Hence, major complications may be rare and may only be determined in studies with larger patient samples. Registry acquisition also provides a sound basis to record potential and rare adverse events (4,29,34). Importantly, the natural course of metastatic spinal lesions is fatal with intolerable pain. Every therapy providing pain relief and causing no major complications may thus be justified on ethical grounds (12).

**CONCLUSION**

In patients with vertebral metastases who are unresponsive or have contraindications for conventional treatments such as radiation or chemotherapy, RFA is a safe therapy that can be effective to palliate pain. However, there is a substantial lack of evidence to evaluate the applicability of RFA. Further studies should be conducted to help determine the exact patient group that would benefit most from the intervention and to compare individual operation techniques (e.g., differences in RFA techniques, vertebroplasty following RFA, etc.). Study registries may serve this purpose well. Further evaluations of RFA (in combination with vertebroplasty) for longer-term clinical efficacy and complication rates – in particular evaluations comparing RFA with traditional therapies, e.g., radiation – are desirable.

---

**REFERENCES**

7. Proschek D, Kurth A, Proschek P, Vogl TJ, Mack MG. Prospective pilot-study of combined bipolar radiofrequency ablation and application of bone cement in